Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare/Medicaid Prosecutions: Does More Money for Fraud Activities Translate Into More Mega-Settlements?

This article was originally published in RPM Report

Executive Summary

From expanding health care coverage to collecting fees from miscreants, the lead story at HHS took a quick and sharp turn with the unveiling of the President's budget for fiscal 2011. HHS is setting high return standards for its fraud activities: $1.5 in net returns to the government for every dollar spent. Practically, that may drive HHS to press big pharma for big settlements.

You may also be interested in...



Abbott Settlement With DOJ Highlights Feds’ Anti-Fraud Efforts

Abbott will pay $5.47 million to resolve allegations that it paid physicians for teaching assignments, speaking engagements and conferences with the expectation that they would in return facilitate product purchases at their hospitals.

Abbott Settlement With DOJ Highlights Feds’ Anti-Fraud Efforts

Abbott will pay $5.47 million to resolve allegations that it paid physicians for teaching assignments, speaking engagements and conferences with the expectation that they would in return facilitate product purchases at their hospitals.

An Involuntary User Fee: Two Ideas for Off-Label Promotion Fines

What if off-label promotion fines were put to good use? A consumer representative and a Senator have thrown out ideas for how to use them.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080648

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel